Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | YWHAG | P61981 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14875455 | 0.84 | KDM4E (0.54) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL30664595 | 0.84 | KDM4E (0.54) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL10293427 | 0.82 | KDM4E (0.46) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL10261801 | 0.82 | HTT (0.68) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL10293476 | 0.81 | ALDH1A1 (0.55) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL10293457 | 0.81 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2KDM4EMAPTMEN1 | |
| SCHEMBL31454335 | 0.80 | MAPT (0.56) | ALDH1A1SMN1; SMN2MAPK1KDM4EMAPT | |
| SCHEMBL422548 | 0.80 | MAPT (0.56) | ALDH1A1SMN1; SMN2MAPK1KDM4EMAPT | |
| SCHEMBL853123 | 0.79 | ALDH1A1 (0.54) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL28843901 | 0.79 | ALDH1A1 (0.52) | ALDH1A1NPSR1SMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-9334282-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-10 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| US-8524716-B2 | Macrocyclic indoles as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2013-09-03 | — | — | US | disclosed |
| EP-2238142-B1 | Macrocyclic indoles as hepatitis c virus inhibitors | JANSSEN R & D IRELAND (IE) | 2012-07-04 | — | — | EP | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267511-A1 | Macrocyclic Indoles as Hepatitis C Virus Inhibitors | IDO1, HCCS, IDO2 | ALDH1A1 802/4885NPSR1 338/4885SMN1; SMN2 4309/4885 |
| US-20100273792-A1 | MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, IDO2 | ALDH1A1 802/4885NPSR1 338/4885SMN1; SMN2 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.